GlassScriptPhysician profile
Andrew D Ta
NPI 1356367338
$13,647.79
in general payments reported to CMS, 2019-2025
57 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,297 · 2020: $2,065 · 2021: $3,177 · 2022: $2,557 · 2023: $1,552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,443.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,443.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,197.38 | 2019-2023 | |
| Genzyme Corporation | $1,133.99 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $829.06 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $758.94 | 2019-2022 | |
| Biogen, INC. | $684.13 | 2019-2023 | Vumerity, Tysabri, Avonex |
| Genentech USA, INC. | $623.15 | 2019-2023 | Enspryng, Ocrevus |
| Lundbeck LLC | $601.55 | 2019-2023 | Vyepti, Rexulti |
| Lilly USA, LLC | $542.83 | 2019-2023 | Reyvow, Emgality, Amyvid |
| Janssen Pharmaceuticals, INC | $479.10 | 2021-2022 | |
| Ucb, INC. | $407.49 | 2019-2022 | |
| Emd Serono, INC. | $399.75 | 2019-2023 | Mavenclad |
| Amneal Pharmaceuticals LLC | $399.09 | 2019-2023 | Rytary |
| Abbvie INC. | $356.69 | 2019-2023 | Vraylar, Ubrelvy |
| Supernus Pharmaceuticals, INC. | $342.75 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $294.71 | 2019-2022 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Ta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.